Verastem (VSTM) Accounts Payables (2011 - 2026)
Verastem's quarterly Accounts Payables came in at $9.6 million in Q1 2026, up 33.38% year-on-year from $7.2 million in Q1 2025, and down 22.86% quarter-over-quarter from $12.4 million in Q4 2025.
Verastem has reported Accounts Payables for 16 years, with the latest figure at $9.6 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 33.38% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.6 million (up 33.38% YoY), and the FY2025 full-year result was $12.4 million, up 209.19% from the prior year.
- Accounts Payables for Q1 2026 stood at $9.6 million, down from $12.4 million in the prior quarter.
- The five-year high for Accounts Payables was $12.4 million in Q4 2025, with the low at $1.7 million in Q2 2022.
- Average Accounts Payables over 5 years is $6.3 million, with a median of $5.4 million recorded in 2022.
- Year-over-year, Accounts Payables surged 736.04% in 2022 and plunged 43.96% in 2024.
- Tracing VSTM's Accounts Payables over 5 years: stood at $4.9 million in 2022, then surged by 46.58% to $7.2 million in 2023, then sank by 43.96% to $4.0 million in 2024, then soared by 209.19% to $12.4 million in 2025, then fell by 22.86% to $9.6 million in 2026.
- The last three Accounts Payables figures came in at $9.6 million (Q1 2026), $12.4 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 9.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.60 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Sep 30, 2025 | 9.89 Mn |
| Jun 30, 2025 | 8.05 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 6.68 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.18 Mn |
| Sep 30, 2023 | 5.12 Mn |
| Jun 30, 2023 | 4.55 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Sep 30, 2022 | 5.36 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 2.90 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 641,000.00 |
| Jun 30, 2021 | 1.40 Mn |
| Mar 31, 2021 | 2.45 Mn |
| Dec 31, 2020 | 1.88 Mn |
| Sep 30, 2020 | 4.68 Mn |
| Jun 30, 2020 | 2.24 Mn |
| Mar 31, 2020 | 7.23 Mn |
| Dec 31, 2019 | 9.66 Mn |
| Sep 30, 2019 | 8.84 Mn |
| Jun 30, 2019 | 11.54 Mn |
| Mar 31, 2019 | 8.59 Mn |
| Dec 31, 2018 | 10.25 Mn |
| Sep 30, 2018 | 11.25 Mn |
| Jun 30, 2018 | 8.51 Mn |
| Mar 31, 2018 | 7.27 Mn |
| Dec 31, 2017 | 9.19 Mn |
| Sep 30, 2017 | 7.36 Mn |
| Jun 30, 2017 | 6.83 Mn |
| Mar 31, 2017 | 8.81 Mn |
| Dec 31, 2016 | 4.10 Mn |
| Sep 30, 2016 | 1.96 Mn |
| Jun 30, 2016 | 2.15 Mn |
| Mar 31, 2016 | 2.60 Mn |
| Dec 31, 2015 | 3.94 Mn |
| Sep 30, 2015 | 3.65 Mn |
| Jun 30, 2015 | 3.00 Mn |
| Mar 31, 2015 | 3.95 Mn |
| Dec 31, 2014 | 3.22 Mn |
| Sep 30, 2014 | 3.30 Mn |
| Jun 30, 2014 | 3.16 Mn |
| Mar 31, 2014 | 2.52 Mn |
| Dec 31, 2013 | 2.76 Mn |
| Sep 30, 2013 | 1.84 Mn |
| Jun 30, 2013 | 2.03 Mn |
| Mar 31, 2013 | 1.93 Mn |
| Dec 31, 2012 | 1.85 Mn |
| Sep 30, 2012 | 1.74 Mn |
| Jun 30, 2012 | 2.45 Mn |
| Mar 31, 2012 | 1.94 Mn |
| Dec 31, 2011 | 2.27 Mn |